Back to jobs

Vice President, Neuroscience Pharmacology and Translational Biomarkers

New Haven, CT

 

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC® androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#TeamArvinas is made up of approximately 450 passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company’s values and mission – to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC® protein degradation platform. We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. But don’t just take our word for it – learn more about life at Arvinas and what employees have to say.

 

Position Summary

The Vice President  of Neuroscience Pharmacology and Translational Biomarkers is responsible for enterprise leadership of  all aspects of driving the neuroscience portfolio. This includes managing exploratory new target selection, generation of in vitro and in vivo data used to develop pharmacokinetic / pharmacodynamic relationships, and the identification of translational biomarkers to support lead optimization and clinical development of PROTAC degrader molecules for severe neurologic disorders. 

This position reports to the Chief Scientific Officer and will be located at our headquarters in New Haven, CT.

 

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

  • Defines, revises and champions asset discovery and development strategies while implementing plans to support prioritization and expeditious progression of the neuroscience portfolio.
  • Builds, leads and inspires a high-performing team through mentorship and development of leadership, scientific and technical capabilities.
  • Enables team to make critical choices in identifying and developing appropriate preclinical in vivo models to support lead identification and optimization based on a deep understanding of disease and target biology, downstream pathways, and target-dependent functional endpoints. Guides team of scientists to build high-quality reliable ex vivo target engagement assays, pathway biology assays, and disease biomarker assays to support preclinical pharmacology studies.
  • Contributes to the design and data analysis strategy of preclinical pharmacology studies to characterize compound activity and establish pharmacokinetic and pharmacodynamic relationships to drive compound optimization and inform human dose projections.
  • Owns and develops the early clinical biomarker strategy across the neuroscience portfolio.
  • Manages the team to develop and execute high quality robust qualified assays to quantify translational biomarkers for targets for tauopathies, Parkinson’s Disease, Huntington’s disease, and other neurodegenerative diseases.
  • Identifies and manages collaborations with contract research organizations and academic labs for the transfer of translational biomarker assays, method development, validation, and clinical execution.
  • Serves as key contributor to preclinical study reports and documents to support Regulatory (IND/ CTA) filings, Investigator Brochures, and clinical study protocols and lab manuals.
  • Works effectively with cross-functional program and development teams to lead programs and strategically progress the pipeline (this includes Go/ No Go decisions based on quality data from in vivo pharmacology or biomarker-based studies)
  • Mentors leaders, develops staff, and promotes culture of collaboration and teamwork.

Qualifications

  • Established scientific reputation with strong knowledge of statistics in the assessment of disease-relevant in vivo models and biomarker endpoints to support neurodegeneration research and development efforts as evidenced by strong publication record, and relationships with key opinion leaders. 
  • Strong leadership experience in initiating xternal science, collaborations, and relationships with academic research teams, CROs, and patient advocacy groups. 
  • Demonstrated expertise in, and leader of a team responsible for, in vivo pharmacology in preclinical models and translational human biomarkers using clinical samples.  
  • Examples of contributions to exploratory neuroscience target selection and demonstrated ability to use in vitro pharmacology data to drive program decisions and portfolio build. 
  • Clear track record of authoring relevant sections of IND/ CTA documents and contributions to clinical protocol design. 
  • Demonstrated ability to lead directly and cross-functionally; recruit, mentor, develop, and motivate a team of creative, experienced scientists to deliver program / portfolio decisions. 
  • Communicates effectively with leadership, employees, colleagues, leadership teams, and the broader external neuroscience community as evidenced by publications, presentations, inventions, and contributions to regulatory filings for clinical candidates. 
  • Confident self-starter with a strong work ethic, who holds self and others accountable in the context of greater portfolio deliverables. 

Education 

  • Ph.D., with 15+ years of industry/ biotech leadership experience in neurobiology and pharmacology with clear contributions to clinical candidates.

 

#LI-New Haven, CT

Arvinas is proud to offer a competitive package of base and incentive compensation as well as a comprehensive benefits program designed to support the health, wellness and financial security of our employees and their families. Benefits include group medical, vision and dental coverage, group and supplemental life insurance, and much more. To learn more about Arvinas, please visit www.arvinas.com

Arvinas is an Equal Opportunity Employer   

Create a Job Alert

Interested in building your career at Arvinas? Get future opportunities sent straight to your email.

Create alert

Apply for this job

*

indicates a required field

Resume/CV

Accepted file types: pdf, doc, docx, txt, rtf

Cover Letter

Accepted file types: pdf, doc, docx, txt, rtf

Education

Select...
Select...
Select...
Select...
Select...
Select...

Voluntary Self-Identification

For government reporting purposes, we ask candidates to respond to the below self-identification survey. Completion of the form is entirely voluntary. Whatever your decision, it will not be considered in the hiring process or thereafter. Any information that you do provide will be recorded and maintained in a confidential file.

As set forth in Arvinas’s Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law.

Select...
Select...
Race & Ethnicity Definitions

If you believe you belong to any of the categories of protected veterans listed below, please indicate by making the appropriate selection. As a government contractor subject to the Vietnam Era Veterans Readjustment Assistance Act (VEVRAA), we request this information in order to measure the effectiveness of the outreach and positive recruitment efforts we undertake pursuant to VEVRAA. Classification of protected categories is as follows:

A "disabled veteran" is one of the following: a veteran of the U.S. military, ground, naval or air service who is entitled to compensation (or who but for the receipt of military retired pay would be entitled to compensation) under laws administered by the Secretary of Veterans Affairs; or a person who was discharged or released from active duty because of a service-connected disability.

A "recently separated veteran" means any veteran during the three-year period beginning on the date of such veteran's discharge or release from active duty in the U.S. military, ground, naval, or air service.

An "active duty wartime or campaign badge veteran" means a veteran who served on active duty in the U.S. military, ground, naval or air service during a war, or in a campaign or expedition for which a campaign badge has been authorized under the laws administered by the Department of Defense.

An "Armed forces service medal veteran" means a veteran who, while serving on active duty in the U.S. military, ground, naval or air service, participated in a United States military operation for which an Armed Forces service medal was awarded pursuant to Executive Order 12985.

Select...

Voluntary Self-Identification of Disability

Form CC-305
Page 1 of 1
OMB Control Number 1250-0005
Expires 04/30/2026

Why are you being asked to complete this form?

We are a federal contractor or subcontractor. The law requires us to provide equal employment opportunity to qualified people with disabilities. We have a goal of having at least 7% of our workers as people with disabilities. The law says we must measure our progress towards this goal. To do this, we must ask applicants and employees if they have a disability or have ever had one. People can become disabled, so we need to ask this question at least every five years.

Completing this form is voluntary, and we hope that you will choose to do so. Your answer is confidential. No one who makes hiring decisions will see it. Your decision to complete the form and your answer will not harm you in any way. If you want to learn more about the law or this form, visit the U.S. Department of Labor’s Office of Federal Contract Compliance Programs (OFCCP) website at www.dol.gov/ofccp.

How do you know if you have a disability?

A disability is a condition that substantially limits one or more of your “major life activities.” If you have or have ever had such a condition, you are a person with a disability. Disabilities include, but are not limited to:

  • Alcohol or other substance use disorder (not currently using drugs illegally)
  • Autoimmune disorder, for example, lupus, fibromyalgia, rheumatoid arthritis, HIV/AIDS
  • Blind or low vision
  • Cancer (past or present)
  • Cardiovascular or heart disease
  • Celiac disease
  • Cerebral palsy
  • Deaf or serious difficulty hearing
  • Diabetes
  • Disfigurement, for example, disfigurement caused by burns, wounds, accidents, or congenital disorders
  • Epilepsy or other seizure disorder
  • Gastrointestinal disorders, for example, Crohn's Disease, irritable bowel syndrome
  • Intellectual or developmental disability
  • Mental health conditions, for example, depression, bipolar disorder, anxiety disorder, schizophrenia, PTSD
  • Missing limbs or partially missing limbs
  • Mobility impairment, benefiting from the use of a wheelchair, scooter, walker, leg brace(s) and/or other supports
  • Nervous system condition, for example, migraine headaches, Parkinson’s disease, multiple sclerosis (MS)
  • Neurodivergence, for example, attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder, dyslexia, dyspraxia, other learning disabilities
  • Partial or complete paralysis (any cause)
  • Pulmonary or respiratory conditions, for example, tuberculosis, asthma, emphysema
  • Short stature (dwarfism)
  • Traumatic brain injury
Select...

PUBLIC BURDEN STATEMENT: According to the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless such collection displays a valid OMB control number. This survey should take about 5 minutes to complete.